This is an outdated version published on 2021-01-05. Read the most recent version.

Weaponized Pathogens and the SARS-CoV-2 Pandemic


  • John W. Oller, Jr.



avian influenza (HPAI), bioweapons research, coronaviruses, COVID-19 pandemic, chronic noncommunicable diseases, dual use research, flu vaccines, gain of function, H1N1, H5N1, H7N9, Middle East respiratory syndrome (MERS), severe acute respiratory syndrome (SARS), SARS-CoV-2, weaponized pathogens


This review zeros in on the aspect of vaccine theory, practice, and research that is the most dangerous, the most controversial, and that is at the epicenter of the alleged SARS-CoV-2 “pandemic”. Regardless whether the “pandemic” itself is real or an illusion manufactured out of fear by vested interests, it is central to ethics and policy discussions seeking to understand bioweapons research in general. The official involvement of the USA in civilian bioweapons research dates at least from World War II under President Franklin Delano Roosevelt. The historical records, cloaked in secrecy until after the Anthrax mailing of 2001, reveal an intimate connection to vaccine research and development, its governmental protection from public scrutiny, and from citizen initiated lawsuits. It is an industry that has released dangerous weaponized pathogens by accident and by sinister designs supposedly compensated in the peace-loving nations by unrealistic hopes in non-existent counter-measures for outbreaks, including epidemiological tracking after the fact, vaccines being researched to counter the weaponization of pathogens being studied, immunity enhancing drugs, and downstream hoped for blood sera containing antibodies. Critical questions concern the ratio of real-risks to hoped-for-benefits, the “mitigating” measures “governments” (especially in the USA) have supposedly established to prevent pandemic outbreaks from bioweapons research, and how all that has played out in the instance of SARS-CoV-2.




How to Cite

Oller, Jr., J. W. (2021). Weaponized Pathogens and the SARS-CoV-2 Pandemic. International Journal of Vaccine Theory, Practice, and Research, 1(2), 172–208.